Related Experiment Video

Updated: Apr 17, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.6K

Cerebroprotective effects of angiotensin II (AT 1) receptor antagonists?

W Drenthen, A A Voors, J L J Kappelle

    Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation
    |February 20, 2015
    PubMed

    Insights

    Angiotensin receptor blockers (ARBs) administered during acute stroke phases improve survival and reduce cardiovascular issues. ARBs also demonstrate stroke prevention benefits, potentially through AT2 receptor stimulation, independent of blood pressure reduction.

    Area of Science:

    • Cardiology
    • Neurology
    • Pharmacology

    Background:

    • The Acute Candesartan Cilexetil Therapy in Stroke Survivors (ACCESS) study investigated the effects of angiotensin receptor blockers (ARBs) in acute stroke.
    • Antihypertensive trials indicate ARBs possess stroke-preventive properties.
    • Animal studies suggest AT2 receptor stimulation by ARBs may reduce cerebral infarct size and mortality.

    Approach:

    • This report reviews pathophysiological mechanisms and clinical data.
    • Evidence for cerebroprotective effects of ARBs is examined.
    • The review focuses on effects independent of blood pressure modulation.

    Key Points:

    • Treatment with ARBs in the acute phase of stroke is associated with improved outcomes.
    • ARBs have demonstrated efficacy in preventing stroke in comparative trials.
    • AT2 receptor activation by ARBs shows promise in reducing stroke-related brain damage and mortality.

    Conclusions:

    • ARBs may offer cerebroprotective benefits beyond their antihypertensive actions.
    • Further research into ARBs' role in stroke management and prevention is warranted.
    • The findings support considering ARBs for neuroprotection in stroke survivors.

    Keywords:
    angiotensincerebral ischaemiacerebrovascular circulationstroke

    More Related Videos

    Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice07:21

    Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

    Published on: September 28, 2015

    40.0K
    Utilizing a Cranial Window to Visualize the Middle Cerebral Artery During Endothelin-1 Induced Middle Cerebral Artery Occlusion07:43

    Utilizing a Cranial Window to Visualize the Middle Cerebral Artery During Endothelin-1 Induced Middle Cerebral Artery Occlusion

    Published on: February 22, 2013

    15.5K

    Related Concept Videos

    Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

    Antihypertensive Drugs: Angiotensin II Receptor Blockers

    In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
    3.1K
    Antihypertensive Drugs: Direct Renin Inhibitors01:25

    Antihypertensive Drugs: Direct Renin Inhibitors

    The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
    1.9K
    Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

    Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

    Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
    2.9K
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    1.5K
    Antihypertensive Drugs: Action of β1 Blockers01:17

    Antihypertensive Drugs: Action of β1 Blockers

    β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
    2.3K
    Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

    Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

    α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
    α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
    1.9K